rabbit anti bard1  (Proteintech)

Journal: Journal of Nanobiotechnology

Article Title: Fisetin-loaded nanoparticles as a novel approach for cholesterol regulation in hypercholesterolemia: targeting the ASGR1-mediated mTORC1/AMPK pathway

doi: 10.1186/s12951-026-04181-z

Figure Lengend Snippet: Fisetin reduced the co-localization between ASGR1 and lysosomes and regulated mTORC1/AMPK-BRCA1/BARD1 pathway. ( A ) Representative immunofluorescence images and statistical results of ASGR1 and CD63 protein expression in AML12 cells. Scale bar (20 μm), magnification (400 ×). ( B-G ) Western blot analysis of p-mTOR, p-S6K, p-AMPK, BRCA1 and BARD1 in AML12 cells. Data are mean ± SD, n = 3. * p < 0.05, ** p < 0.01

Article Snippet: Antibodies are involved in this paper as follows: anti-HMGCR antibody (HuaBio, Hangzhou, China, ET1702-41, 1:5000), anti-LDLR antibody (Santa Cruz, Dallas, USA, sc-18823, 1:1000), anti-CYP7A1 antibody (ABclonal, Wuhan, China, A10615, 1:1000), anti-SR-B1 antibody (Proteintech, 21277-1-AP, 1:1000), anti-ABCA1 antibody (Proteintech, 26564-1-AP, 1:1000), anti-ABCG5 antibody (BOSTER, Wuhan, China, A01503-2, 1:1000), anti-ABCG8 antibody (HuaBio, ER1903-17, 1:1000), anti-LXRα antibody (Proteintech, 14351-1-AP, 1:4000), anti-ASGR1 antibody (Proteintech, 11739-1-AP, 1:10,000), anti-p70 S6 Kinase antibody (Abways, Shanghai, China, CY5365, 1:2000), anti-phospho-p70 S6 kinase (T389) antibody (HuaBio, HA721803, 1:2000), anti-AMPKα antibody (Abmart, TA6423, 1:1000), anti-phospho-AMPKα (Thr172) antibody (Abmart, T55608 , 1:1000), anti-phospho-mTOR antibody (Abmart, T55996 , 1:1000), anti-mTOR antibody (Abmart, T55306 , 1:1000), anti-BRCA1 antibody (Immunoway, Plano, USA, YT0517, 1:1000) and anti-BARD1 antibody (Santa Cruz, sc-74559, 1:500).

Techniques: Immunofluorescence, Expressing, Western Blot

Journal: Journal of Nanobiotechnology

Article Title: Fisetin-loaded nanoparticles as a novel approach for cholesterol regulation in hypercholesterolemia: targeting the ASGR1-mediated mTORC1/AMPK pathway

doi: 10.1186/s12951-026-04181-z

Figure Lengend Snippet: Fisetin regulated mTORC1/AMPK-BRCA1/BARD1 pathway in mice. ( A-F ) Western blot analysis of p-mTOR, p-S6K, p-AMPK, BRCA1 and BARD1 in mice. Data are mean ± SD, n = 3. * p < 0.05, ** p < 0.01

Article Snippet: Antibodies are involved in this paper as follows: anti-HMGCR antibody (HuaBio, Hangzhou, China, ET1702-41, 1:5000), anti-LDLR antibody (Santa Cruz, Dallas, USA, sc-18823, 1:1000), anti-CYP7A1 antibody (ABclonal, Wuhan, China, A10615, 1:1000), anti-SR-B1 antibody (Proteintech, 21277-1-AP, 1:1000), anti-ABCA1 antibody (Proteintech, 26564-1-AP, 1:1000), anti-ABCG5 antibody (BOSTER, Wuhan, China, A01503-2, 1:1000), anti-ABCG8 antibody (HuaBio, ER1903-17, 1:1000), anti-LXRα antibody (Proteintech, 14351-1-AP, 1:4000), anti-ASGR1 antibody (Proteintech, 11739-1-AP, 1:10,000), anti-p70 S6 Kinase antibody (Abways, Shanghai, China, CY5365, 1:2000), anti-phospho-p70 S6 kinase (T389) antibody (HuaBio, HA721803, 1:2000), anti-AMPKα antibody (Abmart, TA6423, 1:1000), anti-phospho-AMPKα (Thr172) antibody (Abmart, T55608 , 1:1000), anti-phospho-mTOR antibody (Abmart, T55996 , 1:1000), anti-mTOR antibody (Abmart, T55306 , 1:1000), anti-BRCA1 antibody (Immunoway, Plano, USA, YT0517, 1:1000) and anti-BARD1 antibody (Santa Cruz, sc-74559, 1:500).

Techniques: Western Blot

Journal: Journal of Nanobiotechnology

Article Title: Fisetin-loaded nanoparticles as a novel approach for cholesterol regulation in hypercholesterolemia: targeting the ASGR1-mediated mTORC1/AMPK pathway

doi: 10.1186/s12951-026-04181-z

Figure Lengend Snippet: Overexpression of ASGR1 abrogated the protective effects of fisetin on AML12 cells. ( A ) mRNA expression levels of ASGR1. ( B-C ) Western blot analysis of ASGR1. ( D ) Levels of serum TC. ( E ) Levels of serum TG. ( F-N ) Western blot analysis of p-S6K, p-mTOR, p-AMPK, BRCA1, BARD1, LXRα, ABCG5 and ABCG8 in AML12 cells. Data are mean ± SD, n = 3. * p < 0.05, ** p < 0.01

Article Snippet: Antibodies are involved in this paper as follows: anti-HMGCR antibody (HuaBio, Hangzhou, China, ET1702-41, 1:5000), anti-LDLR antibody (Santa Cruz, Dallas, USA, sc-18823, 1:1000), anti-CYP7A1 antibody (ABclonal, Wuhan, China, A10615, 1:1000), anti-SR-B1 antibody (Proteintech, 21277-1-AP, 1:1000), anti-ABCA1 antibody (Proteintech, 26564-1-AP, 1:1000), anti-ABCG5 antibody (BOSTER, Wuhan, China, A01503-2, 1:1000), anti-ABCG8 antibody (HuaBio, ER1903-17, 1:1000), anti-LXRα antibody (Proteintech, 14351-1-AP, 1:4000), anti-ASGR1 antibody (Proteintech, 11739-1-AP, 1:10,000), anti-p70 S6 Kinase antibody (Abways, Shanghai, China, CY5365, 1:2000), anti-phospho-p70 S6 kinase (T389) antibody (HuaBio, HA721803, 1:2000), anti-AMPKα antibody (Abmart, TA6423, 1:1000), anti-phospho-AMPKα (Thr172) antibody (Abmart, T55608 , 1:1000), anti-phospho-mTOR antibody (Abmart, T55996 , 1:1000), anti-mTOR antibody (Abmart, T55306 , 1:1000), anti-BRCA1 antibody (Immunoway, Plano, USA, YT0517, 1:1000) and anti-BARD1 antibody (Santa Cruz, sc-74559, 1:500).

Techniques: Over Expression, Expressing, Western Blot